Santosh Reddy Sukka

Dr. Santosh Reddy Sukka

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2023 in Immunological Reviews
Verified
Journal Article
Closed access
MSMaaike Schilperoort
Maaike Schilperoort
DNDavid Ngai
David Ngai
SSSantosh Reddy Sukka
Santosh Reddy Sukka
KAKleopatra Avrampou
Kleopatra Avrampou
HSHongxue Shi
Hongxue Shi
ITIra Tabas
Ira Tabas

6 September 2024 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
SSSantosh Reddy Sukka
Santosh Reddy Sukka
PAPatrick B. Ampomah
Patrick B. Ampomah
LDLancia N. F. Darville
Lancia N. F. Darville
DNDavid Ngai
David Ngai
XWXiaobo Wang
Xiaobo Wang
ITIra Tabas
Ira Tabas

2 February 2024 in Journal of Lipid Research
Verified
Journal Article
Open access
YWYating Wang
Yating Wang
BTBrea Tinsley
Brea Tinsley
SSStefano Spolitu
Stefano Spolitu
JZJohn A. Zadroga
John A. Zadroga
SSSantosh Reddy Sukka
Santosh Reddy Sukka
LOLale Ozcan
Lale Ozcan
LDL-C lowering is the main goal of atherosclerotic cardiovascular disease prevention, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is now a validated therapeutic strategy that lowers serum LDL-C and reduces coronary events. Ironically, the most widely used medicine to lower cholesterol, statins, has been shown to increase circulating PCSK9 levels, which limits their efficacy. Here, we show that geranylgeranyl isoprenoids and hepatic Rap1a regulate both basal and statin-induced expression of PCSK9 and contribute to LDL-C homeostasis. Rap1a prenylation and activity is inhibited upon statin treatment, and statin-mediated PCSK9 induction is dependent on geranylgeranyl synthesis and hepatic Rap1a. Accordingly, treatment of mice with a small-molecule activator of Rap1a lowered PCSK9 protein and plasma cholesterol and inhibited statin-mediated PCSK9 induction in hepatocytes. The mechanism involves inhibition of the downstream RhoA-ROCK pathway and regulation of PCSK9 at the post-transcriptional level. These data further identify Rap1a as a novel regulator of PCSK9 protein and show that blocking Rap1a prenylation through lowering geranylgeranyl levels contributes to statin-mediated induction of PCSK9.

16 September 2024 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
SSSantosh Reddy Sukka
Santosh Reddy Sukka
PAPatrick B. Ampomah
Patrick B. Ampomah
LDLancia N. F. Darville
Lancia N. F. Darville
DNDavid Ngai
David Ngai
XWXiaobo Wang
Xiaobo Wang
ITIra Tabas
Ira Tabas

26 October 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
DNDavid Ngai
David Ngai
SCSaheli Chowdhury
Saheli Chowdhury
SSSantosh Reddy Sukka
Santosh Reddy Sukka
GKGeorge Kuriakose
George Kuriakose
BHBrian Havens
Brian Havens
ITIra Tabas
Ira Tabas
The clearance of apoptotic cells by macrophages, termed efferocytosis, activates multiple pro-resolving pathways, but whether there is a common upstream regulator remains unknown. Here, we report that in efferocytosing macrophages, MerTK activation by apoptotic cells rapidly and transiently activates an IKKβ-NFκB/-p38 pathway, which then promotes interleukin-10 (IL-10) production, continuing efferocytosis, and regulatory T cell expansion. The IKKβ and downstream resolution pathways are linked through the transcription factor Myc, the epigenetic modifier ten-eleven translocation-2 (TET2), and the immune checkpoint protein programmed cell death ligand 1 (PD-L1). Deletion of macrophage IKKβ in male mice blocks the above resolution pathways and compromises efferocytosis-mediated tissue repair in a model of thymic injury and in atherosclerosis regression. Thus, our findings illustrate the existence of a unifying upstream signal for efferocytosis-induced resolution, which could suggest therapeutic strategies to enhance multiple tissue resolution pathways and to optimize anti-inflammatory therapies by avoiding blocking IKKβ-NFκB/p38-mediated resolution.